Crucell Announces Registration of Hepavax-Gene in China

10-Dec-2008 - China

Crucell N.V. announced that the Chinese Authorities have released Hepavax-Gene®, a recombinant hepatitis B vaccine, for registration and quality control in China.

"The launch of Hepavax-Gene® is a significant advancement in the expansion of Crucell's business in the highly strategic Chinese vaccine market," said Ronald Brus, Crucell's Chief Executive Officer. "Hepavax-Gene® will contribute significantly to the sustainability of our Chinese operations. The Chinese hepatitis B vaccine market is the world's biggest market with approximately 100 million doses administered yearly."

According to the company, the prospects for Hepavax-Gene® in the Chinese private market are excellent. Hepavax-Gene® will be positioned in the high-end private market segment with a particular focus on young adults. Hepavax-Gene® possesses two decisive advantages; its production is based on Crucell's hansenula polymorpha patented technology and it is 100% free of thiomersal. Thiomersal is a mercury based compound which, in several countries, is being phased out from vaccines given to children to avoid potentially adverse effects.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances